I forget where I have seen you, but whatever. Here is my take on some of these points.
First, on shares, they already have about 1.55B on a fully diluted basis.
Second, on the PFS issue. I will agree that if PFS vs OS was the issue, NWBO might have a decent chance with this trial in front of the FDA.
Problem is, OS in the randomized trial came in very bad. Likely trending worse for the treatment group than those randomized to placebo. Yes, crossover would be expected to close the gap, but nobody would expect it to eliminate it. Even if using DC post progression was just as effective, you would still expect treatment arm to live longer as not everybody crossed over.
We cannot discuss the actual 232 vs 99 randomized OS numbers because NWBO elects not to disclose them. The trial reached the original predefined stopping point early 2017. It reached the number of events for the OS analysis in late 2017.
Going for a long tail, NWBO elected to allow the trial to run until 2018 when they declared it was sufficiently mature to evaluate it.
So sometime in this process (despite at least 1 efficacy IA being performed) they realized they should switch to external controls. Alas the controls are questionably matched.
As far as the FDA, NWBO has not even disclosed plans to submit to them.
EDIT: I see it is SPPI I know you from. I was in and out (long) for several years. Stopped playing years ago thouigh.